Early access

Lenacapavir submitted to the US FDA with an indication for HIV PrEP

20 December 2024. Related: Early access, Antiretrovirals, Treatment access, HIV prevention and transmission.

i-Base guides updated online

5 December 2024. Related: Editorial, Early access.